Reed Jobs, son of Steve Jobs, co-founder of Apple, has made a name for himself in the world of venture capital with his oncology-focused firm, Yosemite. Launched in 2023, Yosemite has been making significant strides in building biotech companies from scratch, leveraging philanthropy and outside investment capital to drive innovation.
In a recent conversation with TechCrunch, Jobs shared his vision for Yosemite’s future, highlighting the firm’s unique approach to venture investing. Unlike traditional VCs, Yosemite is taking a more hands-on approach, working closely with researchers and scientists to identify promising technologies and bring them to market.
One of the key areas of focus for Yosemite is epigenetic gene editing, which has shown tremendous promise in treating various types of cancer. Jobs believes that this technology has the potential to revolutionize the field of oncology and is committed to supporting research and development in this area.
But what really sets Yosemite apart is its commitment to collaboration and open innovation. The firm is not afraid to partner with other VCs, researchers, and industry experts to advance its goals. This approach is paying off, with several of Yosemite’s portfolio companies already showing significant promise.
We spoke with Jobs about his vision for Yosemite, the future of cancer treatment, and what sets his firm apart from others in the industry.
**TechCrunch:** Reed, thanks for taking the time to speak with us today. Can you tell us a bit about your background and how you got involved in venture capital?
**Reed Jobs:** Thanks for having me! I’ve always been passionate about science and technology, and I was fortunate enough to have a front-row seat to some of the most significant innovations of our time through my father’s work at Apple. After completing my education, I decided to pursue a career in venture capital, where I could use my skills and experience to support and drive innovation.
**TechCrunch:** That’s fascinating. Can you tell us more about Yosemite and its focus on oncology?
**Reed Jobs:** Absolutely. We launched Yosemite in 2023 with the goal of building a portfolio of companies that are working on some of the most pressing challenges in oncology. We’re not just looking for companies that have a promising technology or product – we’re looking for those that have a clear vision and strategy for making a meaningful impact.
**TechCrunch:** That’s really interesting. How does Yosemite’s approach to venture investing differ from traditional VCs?
**Reed Jobs:** We take a much more hands-on approach than traditional VCs. We work closely with researchers, scientists, and industry experts to identify promising technologies and bring them to market. We’re not just writing checks – we’re actively working with our portfolio companies to help them succeed.
**TechCrunch:** That’s really impressive. Can you tell us more about your focus on epigenetic gene editing?
**Reed Jobs:** Epigenetic gene editing has shown tremendous promise in treating various types of cancer, and we believe it has the potential to revolutionize the field of oncology. We’re committed to supporting research and development in this area, and we’re already seeing some exciting results from our portfolio companies.
**TechCrunch:** That’s really promising. What about collaboration and open innovation? How does Yosemite approach these areas?
**Reed Jobs:** We believe that collaboration and open innovation are essential for driving progress in oncology. We’re not afraid to partner with other VCs, researchers, and industry experts to advance our goals. This approach is paying off, with several of our portfolio companies already showing significant promise.
**TechCrunch:** That’s really impressive. Finally, what advice would you give to entrepreneurs and researchers who are working on innovative solutions in oncology?
**Reed Jobs:** My advice would be to stay focused on your vision and mission, and don’t be afraid to take risks. Collaboration and open innovation can be incredibly powerful tools for driving progress, so don’t be afraid to partner with others and share your ideas.
This conversation has been edited for clarity and length.
Source: Original article